Noelle E Carlozzi1,2, Nicholas R Boileau3, Jane S Paulsen4, Nancy R Downing5, Rebecca Ready6, Joel S Perlmutter7,8, David Cella9, Kelvin L Chou10, Michael K McCormack11,12, Stacey Barton7, Jin-Shei Lai9. 1. Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA. carlozzi@med.umich.edu. 2. Department of Physical Medicine and Rehabilitation, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Building NCRC B14, Room G216, Ann Arbor, MI, 48109-2800, USA. carlozzi@med.umich.edu. 3. Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA. 4. Departments of Psychiatry, Neurology, and Psychological and Brain Sciences, The University of Iowa, Iowa City, IA, USA. 5. College of Nursing, Texas A&M, Bryan, TX, USA. 6. Department of Psychological and Brain Sciences, University of Massachusetts, Amherst, MA, USA. 7. Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA. 8. Department of Radiology, Washington University in St. Louis, St. Louis, MO, USA. 9. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 10. Department of Neurology, University of Michigan, Ann Arbor, MI, USA. 11. Department of Pathology, Rowan-School of Medicine, Stratford, NJ, USA. 12. Department of Psychiatry, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ, USA.
Abstract
PURPOSE: Individuals with Huntington disease (HD) experience progressive cognitive decline that may appear years before motor manifestations of the disease. These declines have a profound effect on health-related quality of life (HRQOL) over the disease course, and thus it is important that self-report measures of cognitive function are validated for use in longitudinal studies. METHODS: 359 individuals with premanifest or manifest HD completed baseline and at least one follow-up (12- and 24-month) assessment. Neuro-QoL™ Cognitive Function was administered at each time-point. Participants completed a self-reported global rating of cognitive change, as well as performance-based cognitive changes (using the Symbol Digit Modalities Test). Standardized response means (SRMs) and general linear models evaluated whether Neuro-QoL™ Cognitive Function was responsive to change over time with respect to self-reported and performance-based anchors. Test-retest reliability and known-group validity were also examined. RESULTS: Responsiveness was supported by effect sizes that were small in magnitude, but in the expected direction relative to self-reported and performance-based change. General linear models generally supported 12- and 24-month responsiveness relative to self-reported cognitive change and 12-month responsiveness relative to performance-based change. Test-retest reliability was excellent, and the measure exhibited known-group validity. CONCLUSION: Longitudinal analyses generally indicate that the Neuro-QoL™ Cognitive Function measure is sensitive to change over time in individuals with HD. Neuro-QoL Cognitive Function changes reflect self-reported cognitive change at 12 and 24 months and performance-based change at 12 months. This measure may be useful in clinical trials or longitudinal observation studies.
PURPOSE: Individuals with Huntington disease (HD) experience progressive cognitive decline that may appear years before motor manifestations of the disease. These declines have a profound effect on health-related quality of life (HRQOL) over the disease course, and thus it is important that self-report measures of cognitive function are validated for use in longitudinal studies. METHODS: 359 individuals with premanifest or manifest HD completed baseline and at least one follow-up (12- and 24-month) assessment. Neuro-QoL™ Cognitive Function was administered at each time-point. Participants completed a self-reported global rating of cognitive change, as well as performance-based cognitive changes (using the Symbol Digit Modalities Test). Standardized response means (SRMs) and general linear models evaluated whether Neuro-QoL™ Cognitive Function was responsive to change over time with respect to self-reported and performance-based anchors. Test-retest reliability and known-group validity were also examined. RESULTS: Responsiveness was supported by effect sizes that were small in magnitude, but in the expected direction relative to self-reported and performance-based change. General linear models generally supported 12- and 24-month responsiveness relative to self-reported cognitive change and 12-month responsiveness relative to performance-based change. Test-retest reliability was excellent, and the measure exhibited known-group validity. CONCLUSION: Longitudinal analyses generally indicate that the Neuro-QoL™ Cognitive Function measure is sensitive to change over time in individuals with HD. Neuro-QoL Cognitive Function changes reflect self-reported cognitive change at 12 and 24 months and performance-based change at 12 months. This measure may be useful in clinical trials or longitudinal observation studies.
Entities:
Keywords:
Cognition; HDQLIFE; Huntington disease; Longitudinal studies; Outcome assessment (health care); Quality of life
Authors: Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet Journal: J Clin Epidemiol Date: 2006-08-24 Impact factor: 6.437
Authors: Nicola T Lautenschlager; Leon Flicker; Samuel Vasikaran; Peter Leedman; Osvaldo P Almeida Journal: Am J Geriatr Psychiatry Date: 2005-08 Impact factor: 4.105
Authors: Richard C Gershon; Jin Shei Lai; Rita Bode; Seung Choi; Claudia Moy; Tom Bleck; Deborah Miller; Amy Peterman; David Cella Journal: Qual Life Res Date: 2011-08-27 Impact factor: 4.147
Authors: Janet K Williams; Ji-In Kim; Nancy Downing; Sarah Farias; Deborah L Harrington; Jeffrey D Long; James A Mills; Jane S Paulsen Journal: Neuropsychology Date: 2014-07-07 Impact factor: 3.295
Authors: Anthony L Vaccarino; Terrence Sills; Karen E Anderson; Beth Borowsky; David Craufurd; Joseph Giuliano; Lavonne Goodman; Mark Guttman; Peter Kupchak; Aileen K Ho; Jane S Paulsen; Julie C Stout; Daniel P van Kammen; Ken Evans Journal: PLoS Curr Date: 2011-10-25
Authors: Leonard L Sokol; Jonathan P Troost; Benzi M Kluger; Allison J Applebaum; Jane S Paulsen; Danny Bega; Samuel Frank; Joshua M Hauser; Nicholas R Boileau; Colin A Depp; David Cella; Noelle E Carlozzi Journal: Ann Clin Transl Neurol Date: 2021-07-20 Impact factor: 4.511